Induction of HA-1-specific cytotoxic T-cell clones parallels the therapeutic effect of donor lymphocyte infusion

被引:54
作者
Kircher, B
Stevanovic, S
Urbanek, M
Mitterschiffthaler, A
Rammensee, HG
Grünewald, K
Gastl, G
Nachbaur, D
机构
[1] Univ Innsbruck Hosp, Lab Tumour & Immunobiol, Div Haematol & Oncol,Dept Internal Med, Bone Marrow Transplantat Unit, A-6020 Innsbruck, Austria
[2] Univ Tubingen, Dept Immunol, Inst Cellular Biol, D-72074 Tubingen, Germany
[3] Univ Innsbruck Hosp, Dept Internal Med, Div Haematol & Oncol, Lab Mol Genet & Diagnost, A-6020 Innsbruck, Austria
[4] Austria Bone Marrow Donor Registry, Vienna, Austria
关键词
donor lymphocyte infusion; graft-versus-leukaemia effect; graft-versus-host disease; HA-1; minor histocompatibility antigen;
D O I
10.1046/j.1365-2141.2002.03536.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Donor lymphocyte infusions (DLI) can induce a graft-versus-leukaemia (GvL) reaction in patients with relapsed disease. However, the mechanisms involved in remission induction are not completely known. A patient with chemotherapy-refractory relapse 1 year after human leucocyte antigen (HLA)-identical, unrelated stem cell transplantation (SCT) for bcr/abl-positive common acute lymphoblastic leukaemia (ALL) received a DLI from the original donor, and achieved complete cytogenetic and molecular remission concomitantly with extensive graft-versus-host disease (GvHD). Seven CD8(+) , donor-derived, alloreactive T-cell clones were generated by stimulating post-DLI remission cells with the patient's pretransplant mature dendritic cells. The minor histocompatibility antigen (mHag) recognized by these T-cell clones was identified as HA-1, a mHag associated with acute GvHD after SCT. Our finding provides evidence of HA-1-associated GvL effects after DLI that paralleled the eradication of full-blown, chemotherapy-refractory ALL relapse after allogeneic SCT.
引用
收藏
页码:935 / 939
页数:5
相关论文
共 33 条
[1]   Specific human cellular immunity to bcr-abl oncogene-derived peptides [J].
Bocchia, M ;
Korontsvit, T ;
Xu, Q ;
Mackinnon, S ;
Yang, SY ;
Sette, A ;
Scheinberg, DA .
BLOOD, 1996, 87 (09) :3587-3592
[2]   Donor leukocyte infusions in acute lymphocytic leukemia [J].
Collins, RH ;
Goldstein, S ;
Giralt, S ;
Levine, J ;
Porter, D ;
Drobyski, W ;
Barrett, J ;
Johnson, M ;
Kirk, A ;
Horowitz, M ;
Parker, P .
BONE MARROW TRANSPLANTATION, 2000, 26 (05) :511-516
[3]  
Dazzi F, 1999, Curr Opin Hematol, V6, P394, DOI 10.1097/00062752-199911000-00007
[4]  
DEBUEGER M, 1992, J IMMUNOL, V149, P1788
[5]   The minor histocompatibility antigen HA-1: A diallelic gene with a single amino acid polymorphism [J].
den Haan, JMM ;
Meadows, LM ;
Wang, W ;
Pool, J ;
Blokland, E ;
Bishop, TL ;
Reinhardus, C ;
Shabanowitz, J ;
Offringa, R ;
Hunt, DF ;
Engelhard, VH ;
Goulmy, E .
SCIENCE, 1998, 279 (5353) :1054-1057
[6]   IDENTIFICATION OF A GRAFT-VERSUS-HOST DISEASE-ASSOCIATED HUMAN MINOR HISTOCOMPATIBILITY ANTIGEN [J].
DENHAAN, JMM ;
SHERMAN, NE ;
BLOKLAND, E ;
HUCZKO, E ;
KONING, F ;
DRIJFHOUT, JW ;
SKIPPER, J ;
SHABANOWITZ, J ;
HUNT, DF ;
ENGELHARD, VH ;
GOULMY, E .
SCIENCE, 1995, 268 (5216) :1476-1480
[7]  
Eibl B, 1997, GENE CHROMOSOME CANC, V20, P215, DOI 10.1002/(SICI)1098-2264(199711)20:3<215::AID-GCC1>3.0.CO
[8]  
2-5
[9]   Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer [J].
Eibl, B ;
Schwaighofer, H ;
Nachbaur, D ;
Marth, C ;
Gachter, A ;
Knapp, R ;
Bock, G ;
Gassner, C ;
Schiller, L ;
Petersen, F ;
Niederwieser, D .
BLOOD, 1996, 88 (04) :1501-1508
[10]   RECOGNITION OF CLONOGENIC LEUKEMIC-CELLS, REMISSION BONE-MARROW AND HLA-IDENTICAL DONOR BONE-MARROW BY CD8+ OR CD4+ MINOR HISTOCOMPATIBILITY ANTIGEN-SPECIFIC CYTOTOXIC T-LYMPHOCYTES [J].
FABER, LM ;
VANDERHOEVEN, J ;
GOULMY, E ;
OTTER, ALH ;
VANLUXEMBURGHEIJS, SAP ;
WILLEMZE, R ;
FALKENBURG, JHF .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 96 (02) :877-883